Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | NA |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Primary analysis complete |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A Phase 1 clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost regimens utilizing recombinant adenovirus serotype 35 (rAd35) with HIV-1 clade A Env insert and recombinant adenovirus serotype 5 (rAd5) with HIV-1 clade A or B Env inserts in healthy, HIV-1 uninfected adults
Description
HVTN 083 is a Phase I clinical trial to evaluate the safety and immunogenicity of prime/boost regimens using combinations of VRCHIVADV027-00-VP (rAd35), VRCHIVADV038-00-VP (rAd5), and VRCHIVADV052-00-VP (rAd5).
Sign in to see full information about this study and to download study data.
Products
Product info coming soon!Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.